What did Nature report?

Nature reported in August 2026 that independent researcher Shoto David had identified 54 cellular senescence papers that may have used antibodies not suited to their experimental purposes. Five of the papers included Korean researchers, according to Yonhap News.

Which antibody is in question?

The antibody in question detects beta-galactosidase, an enzyme whose activity appears in cellular senescence, a state where cells stop dividing. The antibody was made to target the version of the enzyme found in E. coli bacteria, not the mammalian form. Nature said this makes it less likely to recognize the enzyme in mammalian cells, which could weaken the reliability and reproducibility of the research.

What does the Korean team say?

The Korea Institute of Oriental Medicine team, which published a paper in npj Aging in January 2026, said it chose the antibody based on earlier studies. It checked the supplier's website, Thermo Fisher Scientific, which listed the antibody as used in human, mouse, and rat tissues. The team said the data from this antibody was supplementary and did not greatly affect the paper's conclusions. It plans to repeat the experiments to confirm the results.

Why does this matter beyond one paper?

Nature noted that the impact of the antibody issue must be judged paper by paper. The concern also extends to the supplier. In May, researchers challenged Thermo Fisher Scientific over about 100 western blot validation images in its catalog that appeared manipulated. In August, they reported more than 18,000 suspicious images across products from 15 companies.

For international fans

This story is about research integrity rather than entertainment. It shows how antibody choice can affect scientific results, and why researchers across countries are rechecking published work.